HKSE

0928.HK

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.

0QNO.L

2359.HK

3347.HK

NYSE

Abingdon Health plc engages in the development, manufacture, and distribution of diagnostic devices worldwide. The company offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; PCRD and PCRD FLEX, nucleic acid lateral flow tests used for rapid readouts post isothermal amplification; Abingdon Simply Test, a range of self-tests; and 2019-nCoV Antigen Test, a rapid lateral flow test for the qualitative detection of antigens to SARS-CoV-2. It also provides AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. In addition, the company provides contract manufacturing, nucleic acid lateral flow test customization, and lateral flow development and manufacturing services. Further, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health plc was incorporated in 2008 and is headquartered in York, the United Kingdom.

ABDX.L

ACL.AX

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. ANGLE plc has a partnership agreement with Bio-View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Performance Analysis

Risk Analysis

Optimization

Factor Model

Diagnostics & Research Stock List

Performance Analysis

Risk Analysis

Optimization

Factor Model

Portfolios

Screeners

Community